Media Coverage

Following updated hepatitis C virus screening recommendations issued in 2020, HCV screening in pregnancy accelerated across the country, according to a retrospective cohort study published in Obstetrics & Gynecology. “We wanted to see whether or not the revised guidelines — which came out during the COVID-19 pandemic — had an impact in changing physician [HCV screening] ordering patterns,” Harvey W. Kaufman, MD, MBA, FCAP, a senior medical director at Quest Diagnostics in Secaucus, New Jersey, told Healio.

Quest Diagnostics has been recognized by the American Heart Association to receive their 2022 Award for Meritorious Achievement for our commitment to health care equity. Quest is removing barriers to health care for people in under-served communities and encouraging diversity in health care professionals through sponsorship of the AHA’s Historically Black Colleges and Universities Scholars Program and the Hispanic Serving Institutions Scholars Program.

There has been substantial progress in the proportion of pregnant persons screened for hepatitis C virus, but the testing rates are still low, according to an article published in Obstetrics & Gynecology. Harvey W. Kaufman, M.D., from Quest Diagnostics in Secaucus, New Jersey, and colleagues examined the effect of the 2020 U.S. Centers for Disease Control and Prevention and U.S. Preventive Services Task Force recommendations on HCV screening among pregnant persons.

While there have been opportunities to apply digital pathology technologies for some time for secondary consultations, training and educational settings, and to review cases involving specialty stains, the ability to use digital pathology for a primary read is fairly new,” noted Kristie Dolan, vice president and general manager of oncology at Quest Diagnostics.

A joint study conducted by Quest Diagnostics and the U.S. Centers for Disease Control and Prevention (CDC) has found that while the rate of hepatitis C (HCV) antibody screening increased 145% in pregnant people during the decade-long study period ending in June 2021, less than half of all pregnant people were screened in early 2021.